✦ LIBER ✦

Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

✍ Scribed by B. Smith; D. Cohn; A. Clements; B. Tierney; J. Straughn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost Effectiveness of Concurrent Gemcita

✍ N. Phippen; C. Leath III; J. Chino; E. Jewell; L. Havrilesky; J. Barnett 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Cost effectiveness of concurrent gemcita

✍ N. Phippen; C. Leath; J. Chino; E. Jewell; L. Havrilesky; J. Barnett 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Cost effectiveness of concurrent gemcita

✍ Neil T. Phippen; Charles A. Leath III; Junzo P. Chino; Elizabeth L. Jewell; Laur 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 341 KB

PCN89 A COST EFFECTIVENESS ANALYSIS DEMO

✍ J de Castro Carpeño; A Castro Gómez; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS C

✍ MJ Nuijten; C Holmberg; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB